Acta Med. 2024, 67: 1-11
https://doi.org/10.14712/18059694.2024.13
Spotlight on Carcinosarcoma of the Ovary: A Scoping Review
References
1. D, Devouassoux-Shisheboran M, Ledermann JA, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer 2014; 24(9 Suppl 3): S55–60.
<https://doi.org/10.1097/IGC.0000000000000228>
2. EM, Herzog TJ, Neugut AI, et al. Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome. Gynecol Oncol 2013; 131(1): 42–5.
<https://doi.org/10.1016/j.ygyno.2013.06.034>
<PubMed>
3. V, Cormio G, Camporeale A, et al. Carcinosarcoma of the ovary: Analysis of 13 cases and review of the literature. Oncology 2011; 80(1–2): 102–6.
<https://doi.org/10.1159/000328794>
4. V, Pundir S, Sekhon R, Mishra A, et al. Carcinosarcoma of the Ovary: A Single-Institute Experience with Surgical Cytoreduction and Platinum-Based Chemotherapy. J Gynecol Surg 2019; 35(4): 224–31.
<https://doi.org/10.1089/gyn.2018.0045>
5. LA, van Le L. Carcinosarcoma of the ovary a review. Obstet Gynecol Surv 2009; 64(10): 673–80; quiz 697.
<https://doi.org/10.1097/OGX.0b013e3181b8aff3>
6. F, Halouani A, Saffar K, Bouraoui S. A rare and distinct bilateral ovarian tumor: Carcinosarcoma. Clin Case Rep 2021; 9(12): e05160.
<https://doi.org/10.1002/ccr3.5160>
<PubMed>
7. M, Nowak K, Kordek A, Cymbaluk-Płoska A. Therapeutic management of rare primary ovarian neoplasms: Carcinosarcoma, leiomyosarcoma, melanoma and carcinoid. Int J Environ Res Public Health 2021; 18(15): 7819.
<https://doi.org/10.3390/ijerph18157819>
<PubMed>
8. LP, Gershenson DM. Treatment of Rare Epithelial Ovarian Tumors. Hematol Oncol Clin North Am 2018; 32(6): 1011–1024.
<https://doi.org/10.1016/j.hoc.2018.07.015>
9. Fu J. Management of a rare ovarian carcinosarcoma: A case report and literature review. Exp Ther Med 2022; 24(3), https://doi .org/10.3892/etm.2022.11520.
<https://doi.org/10.3892/etm.2022.11520>
<PubMed>
10. MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: A review of the literature Gynecol Oncol 2012; 125(1): 271–7.
<https://doi.org/10.1016/j.ygyno.2011.12.418>
11. L, Brudner Y, Silverman BG, Hallak M, Bruchim I. Increased incidence with improved survival of gynecologic carcinosarcoma: A population-based study. Eur J Obstet Gynecol Reprod Biol 2021; 266: 106–10.
<https://doi.org/10.1016/j.ejogrb.2021.09.025>
12. Y, Fishman A, Helpman L. Ethnic Disparities for Gynecologic Cancers in Israel. J Racial Ethn Health Disparities 2020; 7(3): 421–7.
<https://doi.org/10.1007/s40615-019-00670-0>
13. TL, Gold MA, McMeekin DS, et al. Carcinosarcoma of the ovary – A case series. Gynecol Oncol 2006; 100(1): 128–32.
<https://doi.org/10.1016/j.ygyno.2005.07.119>
14. JA, Birrer M, del Carmen MG. “Carcinosarcoma of the ovary, fallopian tube, and peritoneum: Prognostic factors and treatment modalities.” Gynecol Oncol 2016; 142(2): 248–54.
<https://doi.org/10.1016/j.ygyno.2016.06.003>
15. P, Majumdar S das, Parida D. Carcinosarcoma of ovary with long-term overall survival. Oncol J India 2019; 3(2): 41.
<https://doi.org/10.4103/oji.oji_32_19>
16. E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary: 19 years of prospective data from a single center. Cancer 2004; 100(10): 2148–53.
<https://doi.org/10.1002/cncr.20256>
17. AL, Chi DS, Ishill NM, Tew WP. Carcinosarcoma of the ovary treated with platinum and taxane: the memorial Sloan-Kettering Cancer Center experience. Gynecol Oncol 2007; 105(3): 657–61.
<https://doi.org/10.1016/j.ygyno.2007.01.037>
18. EM, Herzog TJ, Neugut, et al. Carcinosarcoma of the ovary: Natural history, patterns of treatment, and outcome. Gynecol Oncol 2013; 131(1): 42–5.
<https://doi.org/10.1016/j.ygyno.2013.06.034>
<PubMed>
19. del Carmen MG, Young RH, Schorge JO, Birrer MJ, editors. Uncommon Gynecologic Cancers, Wiley 2014.
20. RL. Molecular characteristics and clinical behaviour of epithelial ovarian cancers. Vol. 555, Cancer Lett 2023; 555: 216057.
<https://doi.org/10.1016/j.canlet.2023.216057>
21. A, Bustamante B, Shan W, et al. Overall survival and adjuvant therapy in women with ovarian carcinosarcoma: A single-institution experience. Diagnostics (Basel) 2019; 9(4): 200.
<https://doi.org/10.3390/diagnostics9040200>
<PubMed>
22. JW, Ouh YT, Chang HK, et al. Trends in Gynecologic Carcinosarcoma Based on Analysis of the Surveillance Epidemiology End Result (SEER) Database. J Clin Med 2023; 12(3): 1188.
<https://doi.org/10.3390/jcm12031188>
<PubMed>
23. C, Tian C, Powell MA, et al. Racial disparities in uterine and ovarian carcinosarcoma: A population-based analysis of treatment and survival. Gynecol Oncol 2020; 157(1): 67–77.
<https://doi.org/10.1016/j.ygyno.2020.01.017>
24. W, Judge MJ, Clarke BA, et al. Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: Recommendations from the International Collaboration on Cancer Reporting (ICCR). Mod Pathol 2015; 28(8): 1101–22.
<https://doi.org/10.1038/modpathol.2015.77>
25. S, Karathanasi A, Zakynthinakis-Kyriakou N, et al. Ovarian carcinosarcoma: Current developments and future perspectives. Crit Rev Oncol Hematol 2019; 134: 46–55.
<https://doi.org/10.1016/j.critrevonc.2018.12.006>
26. E, Manivel JC, Dehner LP, Wick MR. Malignant mixed müllerian tumors: an immunohistochemical study of 47 cases, with histogenetic considerations and clinical correlation. Hum Pathol 1991; 22(3): 215–23.
<https://doi.org/10.1016/0046-8177(91)90153-G>
27. R, Sahoo T. Carcinosarcoma of Ovary, it’s Histopathological, Management and Prognostic Analysis with Review of Literature. J Cancer Tumor Int 2016; 3(2): 1–10.
<https://doi.org/10.9734/JCTI/2016/22769>
28. , Lemrabott E, Errarhay S, Mamouni N, Bouchikhi C, Banani A. Ovarian Carcinosarcoma. Sch J Med Case Rep 2021; 9(4): 421–3.
<https://doi.org/10.36347/sjmcr.2021.v09i04.032>
29. R, Thomakos N, Godfrey K, et al. The effect of epithelial and stromal tumor components on FIGO stages III and IV ovarian carcinosarcomas treated with primary surgery and chemotherapy. Int J Gynecol Cancer 2007; 17(5): 1025–30.
<https://doi.org/10.1111/j.1525-1438.2007.00919.x>
30. WG, Lioe TF, Mcclelland HR, Lamki H. Rhabdomyosarcoma of the uterus: Report of two cases, including one of the spindle cell variant. Int J Gynecol Cancer 2002; 12(1): 128–32.
<https://doi.org/10.1136/ijgc-00009577-200201000-00021>
31. M, Munari G, Carraro V, et al. Mutational and Immunophenotypic Profiling of a Series of 8 Tubo-ovarian Carcinosarcomas Revealed a Monoclonal Origin of the Disease. Int J Gynecol Pathol 2020; 39(4): 305–12.
<https://doi.org/10.1097/PGP.0000000000000645>
32. S, Nazneen S, Kumari A, Kumari S, Choudhary V, Roy VK. A Rare Tumor of the Ovary: Carcinosarcoma Report and Review of Literature. J Obstet Gynaecol India 2016; 66(Suppl 2): 648–50.
<https://doi.org/10.1007/s13224-015-0788-4>
<PubMed>
33. AK, Sorosky JI, Gelder MS, et al. Primary ovarian sarcoma: analysis of prognostic variables and the role of surgical cytoreduction. Cancer 1998; 82(9): 1731–7.
<https://doi.org/10.1002/(SICI)1097-0142(19980501)82:9<1738::AID-CNCR21>3.0.CO;2-4>
34. MS, Rosa DD, Azambuja E, et al. Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 2007; 17(2): 316–24.
<https://doi.org/10.1111/j.1525-1438.2006.00760.x>
35. MA, Delap LM, Sengupta PS, et al. Carcinosarcoma of the ovary. Br J Cancer 2003; 88(5): 654–7.
<https://doi.org/10.1038/sj.bjc.6600770>
<PubMed>
36. K, Kawauchi S, Kaku T, Nakano H, Tsuneyoshi M. Prognostic factors in ovarian carcinosarcoma: a clinicopathological and immunohistochemical analysis of 23 cases. Histopathology 2000; 37(5): 427–36.
<https://doi.org/10.1046/j.1365-2559.2000.01015.x>
37. HG, Jones MA, Goff BA, et al. Malignant mixed müllerian tumors of the ovary. Experience with surgical cytoreduction and combination chemotherapy. Cancer 1995; 76(7): 1209–13.
<https://doi.org/10.1002/1097-0142(19951001)76:7<1209::AID-CNCR2820760717>3.0.CO;2-V>
38. RL, Croy I, Churchman M, et al. Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. Br J Cancer 2022; 127(6): 1034–1042
<https://doi.org/10.1038/s41416-022-01874-8>
<PubMed>
39. F, Biscione A, Moro F, et al. Imaging in gynecological disease (23): clinical and ultrasound characteristics of ovarian carcinosarcoma. Ultrasound Obstet Gynecol 2022; 59(2): 241–247.
<https://doi.org/10.1002/uog.23733>
40. I, Karalok A, Cirik DA, et al. Uterine and Ovarian Carcinosarcomas: Do They Behave Similarly? J Obstet Gynaecol Can 2017; 39(7): 559–563.
<https://doi.org/10.1016/j.jogc.2017.03.098>
41. K, Mori S, Kuwabara K, et al. Primary Ovarian Carcinosarcoma: Cytological, Pathological, Immunocytochemical, and Immunohistochemical Features. OJ Pathology 2021; 11(01): 22–31.
42. S, Zhang X, Tang Q, Zhou M, Jiang D, Yu E. Genetic Analysis and Combined Therapy of Surgery and Chemotherapy for the Progression-Free Survival of a Patient with Ovarian Carcinosarcoma: A Case Report and Literature Review. Onco Targets Ther 2022; 15: 717–25.
<https://doi.org/10.2147/OTT.S363835>
<PubMed>
43. Y. [Paradigm Shift in Ovarian Tumor Pathology from the View of Genomic Abnormalities]. Gan To Kagaku Ryoho 2016; 43(3): 286–9.
44. KY, Ahn HJ, Kessel B. Differences in risk for type 1 and type 2 ovarian cancer in a large cancer screening trial. J Gynecol Oncol 2016; 27(3): e25.
45. V, Bednarikova M, Cibula D, Zikan M. Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management. Expert Rev Anticancer Ther 2016; 16(12): 1311–21.
<https://doi.org/10.1080/14737140.2016.1247699>
46. JD. Serous Tubal Intraepithelial Carcinoma Localizes to the Tubal-peritoneal Junction. Int J Gynecol Pathol 2015; 34(2): 112–20.
<https://doi.org/10.1097/PGP.0000000000000123>
47. S, Satabongkoch N, Suprasert P, Khunamornpong S. Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma. Case Rep Pathol 2016; 2016: 2605045.
48. S, Kornovski Y, Ivanova Y, et al. Ovarian carcinosarcoma with retroperitoneal para-aortic lymph node dissemination followed by an unusual postoperative complication: A case report with a brief literature review. Diagnostics (Basel) 2020; 10(12): 1073.
<https://doi.org/10.3390/diagnostics10121073>
<PubMed>
49. FS, Kohler MF, Marks JR, Bast RC, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol 1994; 83(1): 118–24.
50. MP, Markaki S, Rodolakis A, et al. Clinicopathological features of ovarian carcinosarcomas: a single institution experience. Gynecol Oncol 2005; 96(1): 136–42.
<https://doi.org/10.1016/j.ygyno.2004.09.051>
51. D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, et al. Gynecologic cancer intergroup (GCIG) consensus review for uterine and ovarian carcinosarcoma. Int J Gynecol Cancer 2014; 24(9 Suppl 3): S55–60.
<https://doi.org/10.1097/IGC.0000000000000228>
52. F, Meddah J, el Youssfi M, Benyahia M, Bargach S. Ovarian Carcinosarcoma: A case report and review of literature. Int J Innov Appl Stud 2019; 27(3): 793–796.
53. J, Tang C, Liu P, Hao H. Carcinosarcoma of the ovary: a case report and literature review. Front Oncol 2023; 13: 1278300.
<https://doi.org/10.3389/fonc.2023.1278300>
<PubMed>
54. JA, Growdon WB, Rodriguez N, et al. Carcinosarcoma of the ovary: A case-control study. Gynecol Oncol 2011; 121(3): 477–81.
<https://doi.org/10.1016/j.ygyno.2011.02.023>
55. AM, Fader AN, Nutter B, Rose P, Tseng JH, Escobar PF. Ovarian Carcinosarcoma: Effects of Cytoreductive Status and Platinum-Based Chemotherapy on Survival. Obstet Gynecol Int 2013; 2013: 490508.
<https://doi.org/10.1155/2013/490508>
<PubMed>
56. KC, Kim JJ, Kim DY, et al. Optimal debulking surgery followed by paclitaxel/platinum chemotherapy is very effective in treating ovarian carcinosarcomas: a single center experience. Gynecol Obstet Invest 2011; 72(3): 208–14.
<https://doi.org/10.1159/000323775>
57. R, Guzzo F, Carrara L, et al. Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody. J Exp Clin Cancer Res 2011; 30: 106.
<https://doi.org/10.1186/1756-9966-30-106>
<PubMed>
58. J, Wen H, Ju X, Bi R, Zuo W, Wu X. Clinical Significance of Programmed Death Ligand-1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma. PLoS One. 2017; 12(1): e0170879.
<https://doi.org/10.1371/journal.pone.0170879>
<PubMed>
59. JA, Gonzalez R, Bregar AJ, et al. Patterns of care, predictors and outcomes of chemotherapy for ovarian carcinosarcoma: A National Cancer Database analysis. Gynecol Oncol 2016; 142(1): 38–43.
<https://doi.org/10.1016/j.ygyno.2016.04.025>
60. GM, Siristatidis C, Battista, Chrelias C, Ovarian carcinosarcoma: a case report, diagnosis, treatment and literature review. Hippokratia 2015; 19(3): 256–259.
61. I, Meydanli MM, Turan AT, et al. Carcinosarcoma of the ovary compared to ovarian high-grade serous carcinoma: impact of optimal cytoreduction and standard adjuvant treatment. Int J Clin Oncol 2018; 23(2): 329–37.
<https://doi.org/10.1007/s10147-017-1215-x>
62. MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27(9): 1419–25.
<https://doi.org/10.1200/JCO.2008.19.1684>
<PubMed>
63. DS, Zivanovic O, Levinson KL, et al. The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol 2010; 119(1): 38–42.
<https://doi.org/10.1016/j.ygyno.2010.05.031>
64. MJA, Kos HE, Willemse PHB, et al. Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma. Cancer 2006; 106(3): 589–98.
<https://doi.org/10.1002/cncr.21616>
65. CC, Schrag D, Neville BA, et al. Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. J Natl Cancer Inst 2006; 98(3): 172–80.
<https://doi.org/10.1093/jnci/djj019>
66. C, Romeo C, Vanacker H, Ray-Coquard I. Rare ovarian tumors: An update on diagnosis and treatment. Int J Gynecol Cancer 2020; 30(6): 879–87.
<https://doi.org/10.1136/ijgc-2020-001235>
67. WP, Li N, Zhang YY, et al. Prognostic significance of lymph node metastasis and lymphadenectomy in early-stage ovarian carcinosarcoma. Cancer Manag Res 2018; 10: 1959–68.
<https://doi.org/10.2147/CMAR.S166524>
<PubMed>
68. D, Planchamp F, Chiva L, et al. European society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017; 27(7): 1534–42.
<https://doi.org/10.1097/IGC.0000000000001041>
69. JM, Amendola BE, Perez N, Amendola M, Wu X. The Use of Lattice Radiation Therapy (LRT) in the Treatment of Bulky Tumors: A Case Report of a Large Metastatic Mixed Mullerian Ovarian Tumor. Cureus 2015; 7(11): e389.
70. T, Yonemori K, Nishikawa T, et al. Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. Oncology (Switzerland) 20201; 98(10): 699–705.
71. JA, Matias-Guiu X, Amant F, et al. ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease. Ann Oncol 2024; 35(3): 248–66.
<https://doi.org/10.1016/j.annonc.2023.11.015>
72. GP, Blessing JA, Rosenshein N, Photopulos G, DiSaia PJ. Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study). Am J Obstet Gynecol 1989; 161(2): 309–12.
<https://doi.org/10.1016/0002-9378(89)90507-3>
73. JT, Blessing JA, Beecham J, Homesley H, Yordan E. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol 1991; 9(11): 1962–6.
<https://doi.org/10.1200/JCO.1991.9.11.1962>
74. DM, Kavanagh JJ, Copeland LJ, Edwards CL, Stringer CA, Wharton JT. Cisplatin therapy for disseminated mixed mesodermal sarcoma of the uterus. J Clin Oncol 1987; 5(4): 618–21.
<https://doi.org/10.1200/JCO.1987.5.4.618>
75. J, Blessing J, Degeest K, Look K, Homesley H. Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 93(2): 336–9.
<https://doi.org/10.1016/j.ygyno.2004.01.007>
76. I, Saip P, Eralp Y, et al. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum. Gynecol Oncol 2008; 108(1): 136–40.
<https://doi.org/10.1016/j.ygyno.2007.09.003>
77. M, Chiappa V, Minig L, et al. Platinum, anthracycline, and alkylating agent-based chemotherapy for ovarian carcinosarcoma. Int J Gynecol Cancer 2009; 19(6): 1142–6.
<https://doi.org/10.1111/IGC.0b013e3181a8ef22>
78. REN, Vermorken JB, Reed N, et al. Cisplatin, doxorubicin and ifosfamide in carcinosarcoma of the female genital tract. A phase II study of the European Organization for Research and Treatment of Cancer Gynaecological Cancer Group (EORTC 55923). Eur J Cancer 2003; 39(4): 481–7.
<https://doi.org/10.1016/S0959-8049(02)00740-2>
79. MA, Filiaci VL, Martee, et al. Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients with Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial. J Clin Oncol 2022; 40: 968–77.
<https://doi.org/10.1200/JCO.21.02050>
<PubMed>
80. DK, Alvarez RD, Bakkum-Gamez JN, et al. Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021; 19(2): 191–226.
<https://doi.org/10.6004/jnccn.2021.0007>
81. Shylasree TS, Bryant A, Athavale R. Chemotherapy and/or radiotherapy in combination with surgery for ovarian carcinosarcoma. Cochrane Database Syst Rev 2013; 2020(3).
82. MA, Filiaci VL, Hensley ML, et al. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I–IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial. J Clin Oncol 2019; 37(15_suppl): 5500–5500.
<https://doi.org/10.1200/JCO.2019.37.15_suppl.5500>
83. Da, Illuzzi Jl, Kelly Mg, et al. Carcinosarcoma of the ovary. Int J Gynecol Cancer 2008; 18(1): 22–9.
<https://doi.org/10.1136/ijgc-00009577-200801000-00004>
84. G, Andersson S, Sorbe B. A population-based series of ovarian carcinosarcomas with long-term follow-up. Anticancer Res 2013; 33(3): 1003–8.
85. M, Idei T, Nakayama Y, et al. [A case of advanced ovarian carcinosarcoma that responded remarkably to neoadjuvant chemotherapy of combined CPT-11 and CDDP]. Gan To Kagaku Ryoho 2002; 29(2): 305–8.
86. M, Masuhara K, Miyoshi A, et al. A rare case of ovarian carcinosarcoma successfully treated with the neoadjuvant chemotherapy of paclitaxel and ifosfamide. J Obstet Gynaecol 2011; 31(3): 274–5.
<https://doi.org/10.3109/01443615.2010.549971>
87. GY, Kyran EL, Bedo J, et al. Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin. Cancer Res. 2022; 82(23): 4457–73.
<https://doi.org/10.1158/0008-5472.CAN-21-4012>
<PubMed>
88. F, Bellone S, Buza N, et al. HER2/neu as a potential target for immunotherapy in gynecologic carcinosarcomas. Int J Gynecol Pathol 2012; 31(3): 211–21.
<https://doi.org/10.1097/PGP.0b013e31823bb24d>
<PubMed>
89. G, Bonazzoli E, Bellone S, et al. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression. Clin Cancer Res 2017; 23(19): 5836–45.
<https://doi.org/10.1158/1078-0432.CCR-16-2862>
<PubMed>
90. TL, Gold MA, McMeekin DS, et al. Carcinosarcoma of the ovary – a case series. Gynecol Oncol 2006; 100(1): 128–32.
<https://doi.org/10.1016/j.ygyno.2005.07.119>
91. LR, Garrett A, Eltabbakh GH, Oliva E, Penson R, Fuller AF. Paclitaxel and platinum chemotherapy for malignant mixed müllerian tumors of the ovary. Gynecol Oncol 2002; 85(3): 459–63.
<https://doi.org/10.1006/gyno.2002.6645>
92. JS, Morris R, Malone JM, Munkarah AR. Survival of women diagnosed with malignant, mixed mullerian tumors of the ovary (OMMMT). Gynecol Oncol 2004; 93(2): 506–12.
<https://doi.org/10.1016/j.ygyno.2004.02.016>
93. RR, Rubin SC, Wong G, Saigo PE, Markman M, Hoskins WJ. Mixed mesodermal tumor of the ovary: analysis of prognostic factors in 31 cases. Obstet Gynecol 1992; 80(4): 660–4.
94. S, Karathanasi A, Zakynthinakis-Kyriakou N, et al. Ovarian carcinosarcoma: Current developments and future perspectives. Crit Rev Oncol Hematol 2019; 134: 46–55.
<https://doi.org/10.1016/j.critrevonc.2018.12.006>
95. MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: A review of the literature. Gynecol Oncol 2012; 125(1): 271–7.
<https://doi.org/10.1016/j.ygyno.2011.12.418>
96. P, Beale P, Dalrymple C, Carter J. Malignant mixed mullerian tumour of the ovary: prognostic factor and response of adjuvant platinum-based chemotherapy. Aust N Z J Obstet Gynaecol 2003; 43(1): 61–4.
<https://doi.org/10.1046/j.0004-8666.2003.00003.x>
97. JA, Diver EJ, Clemmer JT, et al. Carcinosarcoma of the ovary compared to papillary serous ovarian carcinoma: a SEER analysis. Gynecol Oncol 2013; 131(1): 46–51.
<https://doi.org/10.1016/j.ygyno.2013.07.097>
98. DW, Erickson BK, Arend RC, Conner MG, Huh WK, Leath CA. Radical surgical cytoreduction in the treatment of ovarian carcinosarcoma. Gynecol Oncol 2014; 133(2): 234–7.
<https://doi.org/10.1016/j.ygyno.2014.03.002>
<PubMed>
99. E, Stewart M, Rye T, et al. Carcinosarcoma of the ovary. Cancer 2004; 100(10): 2148–53.
<https://doi.org/10.1002/cncr.20256>
100. F, Vloeberghs V, Woestenborghs H, Moerman P, Vergote I. Transition of epithelial toward mesenchymal differentiation during ovarian carcinosarcoma tumorigenesis. Gynecol Oncol 2003; 90(2): 372–7.
<https://doi.org/10.1016/S0090-8258(03)00326-3>
101. Yaw Ho G, Kyran EL, Bedo J, et al. Ovarian carcinosarcoma genomics and pre-clinical models highlight the N-MYC 1 pathway as a key driver and susceptibility to EMT-targeting therapy. bioRxiv.
102. A, Abulsoud AI, Fathi D, et al. The role of miRNAs in ovarian cancer pathogenesis and therapeutic resistance – A focus on signaling pathways interplay. Pathol Res Pract 2022; 240: 154222.
<https://doi.org/10.1016/j.prp.2022.154222>
103. AS, Cole JM, Dahl KDC. Emerging and Evolving Ovarian Cancer Animal Models. Cancer Growth Metastasis 2015; 8(Suppl 1): 29–36.
